Digital Diagnostics is a healthcare technology company that designs and implements artificial intelligence (AI) systems that can diagnose disease by analyzing high-quality images.
Digital Diagnostics’ mission is to benefit patients by developing technology to make healthcare easier to access, affordable, available to everyone, and of the highest quality.
Digital Diagnostics’ flagship product, LumineticsCore™, is an AI system designed to diagnose diabetes related eye disease without needing a physician to look at the images. LumineticsCore can help increase patient access to care by bringing diagnostic results to where the patient already is, referring only those patients that need follow-up care and eliminating the need for an additional appointment for most people. This enables providers to close the eye exam for diabetes care gap by offering a specialty level diagnostic exam at the point-of-care.
Digital Diagnostics’ first FDA-cleared product is the AI diagnostic platform Dr. Abramoff had envisioned years earlier. The platform, called LumineticsCore™ (formerly IDx-DR), detects diabetic retinopathy (including macular edema) at the point-of-care. After completing a rigorous prospective, preregistered clinical trial at primary care sites across the country, LumineticsCore became the first FDA-cleared AI diagnostic system to make a diagnosis without physician input at the point-of-care. Since then, Digital Diagnostics has diligently worked from within the healthcare system to establish automated diagnosis as the new standard of care.
Advancing Automated Diagnosis Standards
From real-world clinic launch & EMR integration, to the creation of the first ever autonomous AI CPT® category 1 code for billing and payment, to inclusion in the American Diabetes Association (ADA)’s 2020 Standards of Care in Diabetes, Digital Diagnostics has proven that intelligent diagnostic platforms can be deployed safely and responsibly to improve patient outcomes and increase healthcare productivity.